Bristol Pravachol/Aspirin Patient Compliance Study Suggested By Cmte.
Executive Summary
Bristol-Myers Squibb should submit patient compliance data for its Pravachol/aspirin fixed-dose combination, FDA Cardiovascular-Renal Drugs Advisory Committee members suggested during a Jan. 18 meeting